摘要
神经病理性疼痛是一种常见的慢性疼痛疾病,发病机制复杂且临床治疗效果欠佳。最近研究表明,N-甲基-D-天冬氨酸受体/突触后致密蛋白95/神经元型一氧化氮合酶(NMDAR/PSD-95/n NOS)复合物在神经病理性疼痛中发挥重要作用。研究发现,如果不直接抑制NMDAR或n NOS,选择性阻断NMDAR/PSD-95或者n NOS/PSD-95的相互作用,可以在不影响NMDAR和n NOS生理功能的前提下抑制神经病理性疼痛中NO的病理性释放,可能获得没有明显副作用的安全有效的神经病理性疼痛的治疗药物。故本文对NMDAR/PSD-95/n NOS复合物在神经病理性疼痛中的研究进展进行综述。
Neuropathic pain is a common chronic pain disease, with complex pathogenesis and inefficient clinical treatment. Recent studies have shown that N-methyl-D-aspartic acid receptor/postsynaptic density protein 95/neuronal nitric oxide synthase(NMDAR/PSD-95/n NOS) complex plays an important role in neuropathic pain. Studies found that it may obtain safe and effective drug for treatment of neuropathic pain with no obvious side effects, if a drug do not inhibit the NMDAR or n NOS directly but selectively disrupt the interaction of NMDAR/PSD-95 or PSD-95/n NOS, which can reduce the release of NO in neuropathic pain without affecting the NMDAR and n NOS functions. Therefore, the research progresses of NMDAR/PSD-95/n NOS complex in neuropathic pain are summarized in this paper.
出处
《药学与临床研究》
2015年第2期168-171,共4页
Pharmaceutical and Clinical Research
